Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Krista Dobo

Showing results (1-10 of 10) with videos related to

Pageof 1
Sort By:
Regulatory Toxicology and Pharmacology : RTP|December 12, 2012
Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesisPatricia Ellis, Michelle Kenyon, Krista Dobo
Environmental and Molecular Mutagenesis|August 24, 2024
Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potentialJennifer Cheung, Krista Dobo, Shaofei Zhang, et al.
Science Advances|May 27, 2026
Complex versus simple <i>N</i>-nitrosamines: Comprehensive genotoxicity and in silico carcinogenicity assessment toward future testing paradigmsXiaowen Sun, Maik Schuler, Shaofei Zhang, et al.
Regulatory Toxicology and Pharmacology : RTP|September 26, 2024
N-Nitrosamine drug substance related impurities (NDSRIs) - A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 DaJoel Bercu, Olivier Dirat, Krista Dobo, et al.
Regulatory Toxicology and Pharmacology : RTP|October 15, 2020
Management of pharmaceutical ICH M7 (Q)SAR predictions - The impact of model updatesCatrin Hasselgren, Joel Bercu, Alex Cayley, et al.
Environmental and Molecular Mutagenesis|June 5, 2021
Permitted daily exposure limits for noteworthy N-nitrosaminesGeorge E Johnson, Krista Dobo, Bhaskar Gollapudi, et al.
Regulatory Toxicology and Pharmacology : RTP|February 16, 2016
Principles and procedures for implementation of ICH M7 recommended (Q)SAR analysesAlexander Amberg, Lisa Beilke, Joel Bercu, et al.
Regulatory Toxicology and Pharmacology : RTP|December 19, 2018
Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analysesAlexander Amberg, Roxanne V Andaya, Lennart T Anger, et al.
Regulatory Toxicology and Pharmacology : RTP|June 14, 2019
Genetic toxicology in silico protocolCatrin Hasselgren, Ernst Ahlberg, Yumi Akahori, et al.
Regulatory Toxicology and Pharmacology : RTP|April 22, 2018
In silico toxicology protocolsGlenn J Myatt, Ernst Ahlberg, Yumi Akahori, et al.
Pageof 1

Showing results (1-10 of 10) with videos related to

Sort By:
Pageof 1
Regulatory Toxicology and Pharmacology : RTP|December 12, 2012
Determination of compound-specific acceptable daily intakes for 11 mutagenic carcinogens used in pharmaceutical synthesisPatricia Ellis, Michelle Kenyon, Krista Dobo
Environmental and Molecular Mutagenesis|August 24, 2024
Evaluation of the nitrosamine impurities of ACE inhibitors using computational, in vitro, and in vivo methods demonstrate no genotoxic potentialJennifer Cheung, Krista Dobo, Shaofei Zhang, et al.
Science Advances|May 27, 2026
Complex versus simple <i>N</i>-nitrosamines: Comprehensive genotoxicity and in silico carcinogenicity assessment toward future testing paradigmsXiaowen Sun, Maik Schuler, Shaofei Zhang, et al.
Regulatory Toxicology and Pharmacology : RTP|September 26, 2024
N-Nitrosamine drug substance related impurities (NDSRIs) - A proposal for the addition of subcategories to carcinogenic potency categorization approach categories 1 and 2 for NDSRIs with a molecular weight > 200 DaJoel Bercu, Olivier Dirat, Krista Dobo, et al.
Regulatory Toxicology and Pharmacology : RTP|October 15, 2020
Management of pharmaceutical ICH M7 (Q)SAR predictions - The impact of model updatesCatrin Hasselgren, Joel Bercu, Alex Cayley, et al.
Environmental and Molecular Mutagenesis|June 5, 2021
Permitted daily exposure limits for noteworthy N-nitrosaminesGeorge E Johnson, Krista Dobo, Bhaskar Gollapudi, et al.
Regulatory Toxicology and Pharmacology : RTP|February 16, 2016
Principles and procedures for implementation of ICH M7 recommended (Q)SAR analysesAlexander Amberg, Lisa Beilke, Joel Bercu, et al.
Regulatory Toxicology and Pharmacology : RTP|December 19, 2018
Principles and procedures for handling out-of-domain and indeterminate results as part of ICH M7 recommended (Q)SAR analysesAlexander Amberg, Roxanne V Andaya, Lennart T Anger, et al.
Regulatory Toxicology and Pharmacology : RTP|June 14, 2019
Genetic toxicology in silico protocolCatrin Hasselgren, Ernst Ahlberg, Yumi Akahori, et al.
Regulatory Toxicology and Pharmacology : RTP|April 22, 2018
In silico toxicology protocolsGlenn J Myatt, Ernst Ahlberg, Yumi Akahori, et al.
Pageof 1